United States - English - NLM (National Library of Medicine)

vedco, inc. - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 2 mg in 1 ml - dexamethasone injection 2 mg/ml is indcated for  the treatment of primary bovine ketosis an as an anti-inflammatory agent in the bovine and equine. as supportive therapy, dexamethasone injection 2 mg/ml may be used in the management of vairious rheumatic, allergic dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids.  dexamethasone injection 2 mg/ml may be used intravenously as supportive therapy when an immeidate hormonal response is required. bovine ketosis dexamethasone injection 2 mg/ml is offered for the treatment of primary ktosis.  the gluconeogenic effects of dexamethasone injection 2 mg/ml, when administered intramuscularyly, are generally noted within the first 5 to 12 hours.  when dexamethasone injection 2 mg/ml is used intravenously, the effects may be noted sooner.  blood sugar levels rise to normal levels repidly and genreally rise to above normal levels within 12 to 24 hours.  acetone bodies are reduce to normal concentrations usually witnin 24 hours.  th

United States - English - NLM (National Library of Medicine)

clipper distributing company, llc - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 2 mg in 1 ml - dexamethasone injection 2 mg/ml is indicated for the treatment of primary bovine ketosis and as an anti-inflammatory agent in the bovine and equine. as supportive therapy, dexamethasone injection 2 mg/ml may be used in the management of various rheumatic, allergic, dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids. dexamethasone injection 2 mg/ml may be used intravenously as supportive therapy when an immediate hormonal response is required. bovine ketosis dexamethasone injection 2 mg/ml is offered for the treatment of primary ketosis. the gluconeogenic effects of dexamethasone injection 2 mg/ml, when administered intramuscularly, are generally noted within the first 6 to 12 hours. when dexamethasone injection 2 mg/ml is used intravenously, the effects may be noted sooner. blood sugar levels rise to normal levels rapidly and generally rise to above normal levels within 12 to 24 hours. acetone bodies are reduced to normal concentrations usually within 24 hours. the p

United States - English - NLM (National Library of Medicine)

vettek - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 2 mg in 1 ml - dexamethasone injection 2 mg/ml is indicated for the treatment of primary bovine ketosis and as an anti-inflammatory agent in the bovine and equine. as supportive therapy, dexamethasone injection 2 mg/ml may be used in the management of various rheumatic, allergic, dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids. dexamethasone injection 2 mg/ml may be used intravenously as supportive therapy when an immediate hormonal response is required. bovine ketosis dexamethasone injection 2 mg/ml is offered for the treatment of primary ketosis. the gluconeogenic effects of dexamethasone injection 2 mg/ml, when administered intramuscularly, are generally noted within the first 6 to 12 hours. when dexamethasone injection 2 mg/ml is used intravenously, the effects may be noted sooner. blood sugar levels rise to normal levels rapidly and generally rise to above normal levels within 12 to 24 hours. acetone bodies are reduced to normal concentrations usually within 24 hours. the

United States - English - NLM (National Library of Medicine)

mwi/vetone - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 3 mg in 1 ml - indications and usage: dexamethasone-sp (dexamethasone sodium phosphate) is indicated as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses. contraindications: do not use in viral infections. except when used for emergency therapy, dexamethasone sodium phosphate is contraindicated in animals with tuberculosis and chronic nephritis. existence of congestive heart failure, osteoporosis and diabetes are relative contraindications. in the presence of infection appropriate antibacterial agents should also be administered and should be continued for at least 3 days after discontinuance of the hormone and disappearance of all signs of infection.

United States - English - NLM (National Library of Medicine)

par pharmaceutical inc. - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 0.5 mg - control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis and serum sickness. bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (stevens-johnson syndrome). primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (diamond-blackfan anemia), idiopathic thrombocytopenic purpura in adul

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 0.75 mg - control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis and serum sickness. bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (stevens-johnson syndrome). primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (diamond-blackfan anemia), idiopathic thrombocytopenic purpura in adul

United States - English - NLM (National Library of Medicine)

sti pharma llc - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 0.5 mg in 5 ml - allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: atopic dermatitis, bronchial asthma, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, and serum sickness. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, and acute rheumatic carditis. dermatologic diseases bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome), severe psoriasis, and severe seborrheic dermatitis. edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; i

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 4 mg - control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis and serum sickness. bullous dermatitis herpetiformis, exfoliative erythroderma, mycisis fungoides, pemphigus, and severe erythema multiforme (stevens-johnson syndrome). primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (diamon-blackfan anemia), idiopathic thrombocytopenic purpura in adult

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 0.5 mg in 5 ml - - endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer - rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis - collagen diseases: during an exacerbation or as maintenance therapy in selected cases of: systemic lup

United States - English - NLM (National Library of Medicine)

morton grove pharmaceuticals, inc. - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 0.5 mg in 5 ml - 1.  endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).     congenital adrenal hyperplasia     nonsuppurative thyroiditis     hypercalcemia associated with cancer 2.  rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:     psoriatic arthritis     rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)     ankylosing spondylitis     acute and subacute bursitis     acute nonspecific tenosynovitis     acute gouty arthritis     post-traumatic osteoarthritis     synovitis of osteoarthritis     epicondylitis 3.  collagen diseases: during an exacerbation or as maintenance therapy in selected cases of:     systemic lupus erythematosus     ac